|
1
|
Hemler ME: Tetraspanin proteins mediate
cellular penetration, invasion, and fusion events and define a
novel type of membrane microdomain. Annu Rev Cell Dev Biol.
19:397–422. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Min G, Wang H, Sun TT and Kong XP:
Structural basis for tetraspanin functions as revealed by the
cryo-EM structure of uroplakin complexes at 6-A resolution. J Cell
Biol. 173:975–983. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kitadokoro K, Bordo D, Galli G, Petracca
R, Falugi F, Abrignani S, Grandi G and Bolognesi M: CD81
extracellular domain 3D structure: Insight into the tetraspanin
superfamily structural motifs. EMBO J. 20:12–18. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maecker HT, Todd SC and Levy S: The
tetraspanin superfamily: molecular facilitators. FASEB J.
11:428–442. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boucheix C and Rubinstein E: Tetraspanins.
Cell Mol Life Sci. 58:1189–1205. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Boucheix C, Duc GH, Jasmin C and
Rubinstein E: Tetraspanins and malignancy. Expert Rev Mol Med.
2001:1–17. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tarrant JM, Robb L, van Spriel AB and
Wright MD: Tetraspanins: Molecular organisers of the leukocyte
surface. Trends Immunol. 24:610–617. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Berditchevski F: Complexes of tetraspanins
with integrins: More than meets the eye. J Cell Sci. 114:4143–4151.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Claas C, Stipp CS and Hemler ME:
Evaluation of prototype transmembrane 4 superfamily protein
complexes and their relation to lipid rafts. J Biol Chem.
276:7974–7984. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Garcia-Mayea Y, Mir C, Carballo L,
Sánchez-García A, Bataller M and LLeonart ME: TSPAN1, a novel
tetraspanin member highly involved in carcinogenesis and
chemoresistance. Biochim Biophys Acta Rev Cancer. 1877:1886742022.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Global Burden of Disease 2019 Cancer
Collaboration, . Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL,
Harvey JD, Henrikson HJ, Lu D, Pennini A, et al: Cancer incidence,
mortality, years of life lost, years lived with disability, and
disability-adjusted life years for 29 cancer groups from 2010 to
2019: A systematic analysis for the global burden of disease study
2019. JAMA Oncol. 8:420–444. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Berditchevski F, Gilbert E, Griffiths MR,
Fitter S, Ashman L and Jenner SJ: Analysis of the CD151-alpha3beta1
integrin and CD151-tetraspanin interactions by mutagenesis. J Biol
Chem. 276:41165–41174. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gesierich S, Paret C, Hildebrand D, Weitz
J, Zgraggen K, Schmitz-Winnenthal FH, Horejsi V, Yoshie O, Herlyn
D, Ashman LK and Zöller M: Colocalization of the, tetraspanins
CO-029 and CD151, with integrins in human pancreatic
adenocarcinoma: Impact on cell motility. Clin Cancer Res.
11:2840–2852. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lazo PA: Functional implications of
tetraspanin proteins in cancer biology. Cancer Sci. 98:1666–1677.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li J, Xu J, Li L, Ianni A, Kumari P, Liu
S, Sun P, Braun T, Tan X, Xiang R and Yue S: MGAT3-mediated
glycosylation of tetraspanin CD82 at asparagine 157 suppresses
ovarian cancer metastasis by inhibiting the integrin signaling
pathway. Theranostics. 10:6467–6482. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tiwari-Woodruff SK, Buznikov AG, Vu TQ,
Micevych PE, Chen K, Kornblum HI and Bronstein JM: OSP/claudin-11
forms a complex with a novel member of the tetraspanin super family
and beta1 integrin and regulates proliferation and migration of
oligodendrocytes. J Cell Biol. 153:295–305. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Otsubo C, Otomo R, Miyazaki M,
Matsushima-Hibiya Y, Kohno T, Iwakawa R, Takeshita F, Okayama H,
Ichikawa H, Saya H, et al: TSPAN2 is involved in cell invasion and
motility during lung cancer progression. Cell Rep. 7:527–538. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tardif MR and Tremblay MJ: Tetraspanin
CD81 provides a costimulatory signal resulting in increased human
immunodeficiency virus type 1 gene expression in primary CD4+ T
lymphocytes through NF-kappaB, NFAT, and AP-1 transduction
pathways. J Virol. 79:4316–4328. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Levy S and Shoham T: The tetraspanin web
modulates immune-signalling complexes. Nat Rev Immunol. 5:136–148.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arduise C, Abache T, Li L, Billard M,
Chabanon A, Ludwig A, Mauduit P, Boucheix C, Rubinstein E and Le
Naour F: Tetraspanins regulate ADAM10-mediated cleavage of
TNF-alpha and epidermal growth factor. J Immunol. 181:7002–7013.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yañez-Mó M, Barreiro O, Gonzalo P, Batista
A, Megías D, Genís L, Sachs N, Sala-Valdés M, Alonso MA, Montoya
MC, et al: MT1-MMP collagenolytic activity is regulated through
association with tetraspanin CD151 in primary endothelial cells.
Blood. 112:3217–3226. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bass R, Werner F, Odintsova E, Sugiura T,
Berditchevski F and Ellis V: Regulation of urokinase receptor
proteolytic function by the tetraspanin CD82. J Biol Chem.
280:14811–14818. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lu Z, Luo T, Nie M, Pang T, Zhang X, Shen
X, Ma L, Bi J, Wei G, Fang G and Xue X: TSPAN1 functions as an
oncogene in gastric cancer and is downregulated by miR-573. FEBS
Lett. 589:1988–1994. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun X, Wang M, Zhang F and Kong X:
Inhibition of NET-1 suppresses proliferation and promotes apoptosis
of hepatocellular carcinoma cells by activating the PI3K/AKT
signaling pathway. Exp Ther Med. 17:2334–2340. 2019.PubMed/NCBI
|
|
25
|
Huang H, Li H, Zhao T, Khan AA, Pan R,
Wang S, Wang S and Liu X: TSPAN1-elevated FAM110A promotes
pancreatic cancer progression by transcriptionally regulating
HIST1H2BK. J Cancer. 13:906–917. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen L, Yuan D, Zhao R, Li H and Zhu J:
Suppression of TSPAN1 by RNA interference inhibits proliferation
and invasion of colon cancer cells in vitro. Tumori. 96:744–750.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen Z, Gu S, Trojanowicz B, Liu N, Zhu G,
Dralle H and Hoang-Vu C: Down-regulation of TM4SF is associated
with the metastatic potential of gastric carcinoma TM4SF members in
gastric carcinoma. World J Surg Oncol. 9:432011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
He P, Wang S, Zhang X, Gao Y, Niu W, Dong
N, Shi X, Geng Y, Ma Q, Li M, et al: Tspan5 is an independent
favourable prognostic factor and suppresses tumour growth in
gastric cancer. Oncotarget. 7:40160–40173. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xie Q, Guo H, He P, Deng H, Gao Y, Dong N,
Niu W, Liu T, Li M, Wang S, et al: Tspan5 promotes
epithelial-mesenchymal transition and tumour metastasis of
hepatocellular carcinoma by activating Notch signalling. Mol Oncol.
15:3184–3202. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Roh S, Kim S, Hong I, Lee M, Kim HJ, Ahn
TS, Kang DH, Baek MJ, Kwak HJ, Kim CJ and Jeong D: High expression
of tetraspanin 5 as a prognostic marker of colorectal cancer. Int J
Mol Sci. 24:64762023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Andrijes R, Hejmadi RK, Pugh M, Rajesh S,
Novitskaya V, Ibrahim M, Overduin M, Tselepis C, Middleton GW,
Győrffy B, et al: Tetraspanin 6 is a regulator of carcinogenesis in
colorectal cancer. Proc Natl Acad Sci USA. 118:e20114111182021.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qi Y, Li H, Lv J, Qi W, Shen L, Liu S,
Ding A, Wang G, Sun L and Qiu W: Expression and function of
transmembrane 4 superfamily proteins in digestive system cancers.
Cancer Cell Int. 20:3142020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhu H, Wu Y, Zheng W and Lu S: CO-029 is
overexpressed in gastric cancer and mediates the effects of EGF on
gastric cancer cell proliferation and invasion. Int J Mol Med.
35:798–802. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wei L, Li Y and Suo Z: TSPAN8 promotes
gastric cancer growth and metastasis via ERK MAPK pathway. Int J
Clin Exp Med. 8:8599–8607. 2015.PubMed/NCBI
|
|
35
|
Akiel MA, Santhekadur PK, Mendoza RG,
Siddiq A, Fisher PB and Sarkar D: Tetraspanin 8 mediates
AEG-1-induced invasion and metastasis in hepatocellular carcinoma
cells. FEBS Lett. 590:2700–2708. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li J, Chen X, Zhu L, Lao Z, Zhou T, Zang
L, Ge W, Jiang M, Xu J, Cao Y, et al: SOX9 is a critical regulator
of TSPAN8-mediated metastasis in pancreatic cancer. Oncogene.
40:4884–4893. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Guo Q, Xia B, Zhang F, Richardson MM, Li
M, Zhang JS, Chen F and Zhang XA: Tetraspanin CO-029 inhibits
colorectal cancer cell movement by deregulating cell-matrix and
cell-cell adhesions. PLoS One. 7:e384642012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou Z, Ran YL, Hu H, Pan J, Li ZF, Chen
LZ, Sun LC, Peng L, Zhao XL, Yu L, et al: TM4SF3 promotes
esophageal carcinoma metastasis via upregulating ADAM12m
expression. Clin Exp Metastasis. 25:537–548. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Qi Y, Lv J, Liu S, Sun L, Wang Y, Li H, Qi
W and Qiu W: TSPAN9 and EMILIN1 synergistically inhibit the
migration and invasion of gastric cancer cells by increasing TSPAN9
expression. BMC Cancer. 19:6302019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dash S, Wu CC, Wu CC, Chiang SF, Lu YT,
Yeh CY, You JF, Chu LJ, Yeh TS and Yu JS: Extracellular vesicle
membrane protein profiling and targeted mass spectrometry unveil
CD59 and tetraspanin 9 as novel plasma biomarkers for detection of
colorectal cancer. Cancers (Basel). 15:1772022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu J, Chen C, Li G, Chen D and Zhou Q:
Upregulation of TSPAN12 is associated with the colorectal cancer
growth and metastasis. Am J Transl Res. 9:812–822. 2017.PubMed/NCBI
|
|
42
|
Sidahmed-Adrar N, Ottavi JF, Benzoubir N,
Ait Saadi T, Bou Saleh M, Mauduit P, Guettier C, Desterke C and Le
Naour F: Tspan15 is a new stemness-related marker in hepatocellular
carcinoma. Proteomics. 19:e19000252019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang B, Zhang Z, Li L, Qin YR, Liu H,
Jiang C, Zeng TT, Li MQ, Xie D, Li Y, et al: TSPAN15 interacts with
BTRC to promote oesophageal squamous cell carcinoma metastasis via
activating NF-κB signaling. Nat Commun. 9:14232018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zheng Y, Wang DD, Wang W, Pan K, Huang CY,
Li YF, Wang QJ, Yuan SQ, Jiang SS, Qiu HB, et al: Reduced
expression of uroplakin 1A is associated with the poor prognosis of
gastric adenocarcinoma patients. PLoS One. 9:e930732014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yang YM, Zhang ZW, Liu QM, Sun YF, Yu JR
and Xu WX: Overexpression of CD151 predicts prognosis in patients
with resected gastric cancer. PLoS One. 8:e589902013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu
MY, Xu Y, Song ZJ, Wang ZJ, Wu JC, et al: Role of overexpression of
CD151 and/or c-Met in predicting prognosis of hepatocellular
carcinoma. Hepatology. 49:491–503. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Suzuki S, Miyazaki T, Tanaka N, Sakai M,
Sano A, Inose T, Sohda M, Nakajima M, Kato H and Kuwano H:
Prognostic significance of CD151 expression in esophageal squamous
cell carcinoma with aggressive cell proliferation and invasiveness.
Ann Surg Oncol. 18:888–893. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xu L, Hou Y, Tu G, Chen Y, Du YE, Zhang H,
Wen S, Tang X, Yin J, Lang L, et al: Nuclear Drosha enhances cell
invasion via an EGFR-ERK1/2-MMP7 signaling pathway induced by
dysregulated miRNA-622/197 and their targets LAMC2 and CD82 in
gastric cancer. Cell Death Dis. 8:e26422017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hemler ME, Mannion BA and Berditchevski F:
Association of TM4SF proteins with integrins: Relevance to cancer.
Biochim Biophys Acta. 1287:67–71. 1996.PubMed/NCBI
|
|
50
|
Dong JT, Lamb PW, Rinker-Schaeffer CW,
Vukanovic J, Ichikawa T, Isaacs JT and Barrett JC: KAI1, a
metastasis suppressor gene for prostate cancer on human chromosome
11p11.2. Science. 268:884–886. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liu X, Guo X, Li H, Chen J and Qi X:
Src/STAT3 signaling pathways are involved in KAI1-induced
downregulation of VEGF-C expression in pancreatic cancer. Mol Med
Rep. 13:4774–4778. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Huang X, Li Y, He X, Chen Y, Wei W, Yang X
and Ma K: Gangliosides and CD82 inhibit the motility of colon
cancer by downregulating the phosphorylation of EGFR at different
tyrosine sites and signaling pathways. Mol Med Rep. 22:3994–4002.
2020.PubMed/NCBI
|
|
53
|
Takaoka A, Hinoda Y, Satoh S, Adachi Y,
Itoh F, Adachi M and Imai K: Suppression of invasive properties of
colon cancer cells by a metastasis suppressor KAI1 gene. Oncogene.
16:1443–1453. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Miyazaki T, Kato H, Shitara Y, Yoshikawa
M, Tajima K, Masuda N, Shouji H, Tsukada K, Nakajima T and Kuwano
H: Mutation and expression of the metastasis suppressor gene KAI1
in esophageal squamous cell carcinoma. Cancer. 89:955–962. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zeng TD, Zheng B, Zheng W and Chen C:
CD82/KAI1 inhibits invasion and metastasis of esophageal squamous
cell carcinoma via TGF-β1. Eur Rev Med Pharmacol Sci. 22:5928–5937.
2018.PubMed/NCBI
|
|
56
|
Yoo TH, Ryu BK, Lee MG and Chi SG: CD81 is
a candidate tumor suppressor gene in human gastric cancer. Cell
Oncol (Dordr). 36:141–153. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Fang TT, Sun XJ, Chen J, Zhao Y, Sun RX,
Ren N and Liu BB: Long non-coding RNAs are differentially expressed
in hepatocellular carcinoma cell lines with differing metastatic
potential. Asian Pac J Cancer Prev. 15:10513–10524. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Murayama Y, Miyagawa J, Shinomura Y,
Kanayama S, Isozaki K, Yamamori K, Mizuno H, Ishiguro S, Kiyohara
T, Miyazaki Y, et al: Significance of the association between
heparin-binding epidermal growth factor-like growth factor and CD9
in human gastric cancer. Int J Cancer. 98:505–513. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Nakamoto T, Murayama Y, Oritani K,
Boucheix C, Rubinstein E, Nishida M, Katsube F, Watabe K, Kiso S,
Tsutsui S, et al: A novel therapeutic strategy with anti-CD9
antibody in gastric cancers. J Gastroenterol. 44:889–896. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Li Y, Yu S, Li L, Chen J, Quan M, Li Q and
Gao Y: KLF4-mediated upregulation of CD9 and CD81 suppresses
hepatocellular carcinoma development via JNK signaling. Cell Death
Dis. 11:2992020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Tang M, Yin G, Wang F, Liu H, Zhou S, Ni
J, Chen C, Zhou Y and Zhao Y: Downregulation of CD9 promotes
pancreatic cancer growth and metastasis through upregulation of
epidermal growth factor on the cell surface. Oncol Rep. 34:350–358.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ovalle S, Gutiérrez-López MD, Olmo N,
Turnay J, Lizarbe MA, Majano P, Molina-Jiménez F, López-Cabrera M,
Yáñez-Mó M, Sánchez-Madrid F and Cabañas C: The tetraspanin CD9
inhibits the proliferation and tumorigenicity of human colon
carcinoma cells. Int J Cancer. 121:2140–2152. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Buim ME, Lourenço SV, Carvalho KC, Cardim
R, Pereira C, Carvalho AL, Fregnani JH and Soares FA:
Downregulation of CD9 protein expression is associated with
aggressive behavior of oral squamous cell carcinoma. Oral Oncol.
46:166–171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kusukawa J, Ryu F, Kameyama T and Mekada
E: Reduced expression of CD9 in oral squamous cell carcinoma: CD9
expression inversely related to high prevalence of lymph node
metastasis. J Oral Pathol Med. 30:73–79. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Park SA, Kim MJ, Park SY, Kim JS, Lim W,
Nam JS and Yhong Sheen Y: TIMP-1 mediates TGF-β-dependent crosstalk
between hepatic stellate and cancer cells via FAK signaling. Sci
Rep. 5:164922015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Takashima Y, Komatsu S, Ohashi T, Kiuchi
J, Kamiya H, Shimizu H, Arita T, Konishi H, Shiozaki A, Kubota T,
et al: Overexpression of Tetraspanin31 contributes to malignant
potential and poor outcomes in gastric cancer. Cancer Sci.
113:1984–1998. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Wang J, Zhou Y, Li D, Sun X, Deng Y and
Zhao Q: TSPAN31 is a critical regulator on transduction of survival
and apoptotic signals in hepatocellular carcinoma cells. FEBS Lett.
591:2905–2918. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Smyth EC, Nilsson M, Grabsch HI, van
Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Yang L, Ying X, Liu S, Lyu G, Xu Z, Zhang
X, Li H, Li Q, Wang N and Ji J: Gastric cancer: Epidemiology, risk
factors and prevention strategies. Chin J Cancer Res. 32:695–704.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Deng Y, Cai S, Shen J and Peng H:
Tetraspanins: Novel molecular regulators of gastric cancer. Front
Oncol. 11:7025102021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Hemler ME: Tetraspanin proteins promote
multiple cancer stages. Nat Rev Cancer. 14:49–60. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zöller M: Tetraspanins: Push and pull in
suppressing and promoting metastasis. Nat Rev Cancer. 9:40–55.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Bonnet M, Maisonial-Besset A, Zhu Y,
Witkowski T, Roche G, Boucheix C, Greco C and Degoul F: Targeting
the tetraspanins with monoclonal antibodies in oncology: Focus on
Tspan8/Co-029. Cancers (Basel). 11:1792019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Claas C, Seiter S, Claas A, Savelyeva L,
Schwab M and Zöller M: Association between the rat homologue of
CO-029, a metastasis-associated tetraspanin molecule and
consumption coagulopathy. J Cell Biol. 141:267–280. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Gesierich S, Berezovskiy I, Ryschich E and
Zöller M: Systemic induction of the angiogenesis switch by the
tetraspanin D6.1A/CO-029. Cancer Res. 66:7083–7094. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Anami K, Oue N, Noguchi T, Sakamoto N,
Sentani K, Hayashi T, Naito Y, Oo HZ and Yasui W: TSPAN8,
identified by Escherichia coli ampicillin secretion trap, is
associated with cell growth and invasion in gastric cancer. Gastric
Cancer. 19:370–380. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Hemler ME: Tetraspanin functions and
associated microdomains. Nat Rev Mol Cell Biol. 16:801–811. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Wang HX, Li Q, Sharma C, Knoblich K and
Hemler ME: Tetraspanin protein contributions to cancer. Biochem Soc
Trans. 39:547–552. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Li T, Meng XL and Yang WQ: Long noncoding
RNA PVT1 acts as a ‘sponge’ to inhibit microRNA-152 in gastric
cancer cells. Dig Dis Sci. 62:3021–3028. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Murray D, Horgan G, Macmathuna P and Doran
P: NET1-mediated RhoA activation facilitates lysophosphatidic
acid-induced cell migration and invasion in gastric cancer. Br J
Cancer. 99:1322–1329. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Wang GL, Chen L, Wei YZ, Zhou JM, Wu YY,
Zhang YX, Qin J and Zhu YY: The effect of NET-1 on the
proliferation, migration and endocytosis of the SMMC-7721 HCC cell
line. Oncol Rep. 27:1944–1952. 2012.PubMed/NCBI
|
|
82
|
Shang H, Wu B, Liang X, Sun Y, Han X,
Zhang L, Wang Q and Cheng W: Evaluation of therapeutic effect of
targeting nanobubbles conjugated with NET-1 siRNA by shear wave
elastography: an in vivo study of hepatocellular carcinoma bearing
mice model. Drug Deliv. 26:944–951. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Li T, Xue Y, Wang G, Gu T, Li Y, Zhu YY
and Chen L: Multi-target siRNA: Therapeutic strategy for
hepatocellular carcinoma. J Cancer. 7:1317–1327. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Garcia-Mayea Y, Mir C, Carballo L,
Castellvi J, Temprana-Salvador J, Lorente J, Benavente S,
García-Pedrero JM, Allonca E, Rodrigo JP and LLeonart ME: TSPAN1: A
novel protein involved in head and neck squamous cell carcinoma
chemoresistance. Cancers (Basel). 12:32692020. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ma L, Li Y, Peng J, Wu D, Zhao X, Cui Y,
Chen L, Yan X, Du Y and Yu L: Discovery of the migrasome, an
organelle mediating release of cytoplasmic contents during cell
migration. Cell Res. 25:24–38. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Wu L, Yang S, Li H, Zhang Y, Feng L, Zhang
C, Wei J, Gu X, Xu G, Wang Z and Wang F: TSPAN4-positive migrasome
derived from retinal pigmented epithelium cells contributes to the
development of proliferative vitreoretinopathy. J
Nanobiotechnology. 20:5192022. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Zhang C, Li T, Yin S, Gao M, He H, Li Y,
Jiang D, Shi M, Wang J and Yu L: Monocytes deposit migrasomes to
promote embryonic angiogenesis. Nat Cell Biol. 24:1726–1738. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Zhang Y, Zhang M, Xie Z, Ding Y, Huang J,
Yao J, Lv Y and Zuo J: Research progress and direction of novel
organelle-migrasomes. Cancers (Basel). 15:1342022. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Qi W, Sun L, Liu N, Zhao S, Lv J and Qiu
W: Tetraspanin family identified as the central genes detected in
gastric cancer using bioinformatics analysis. Mol Med Rep.
18:3599–3610. 2018.PubMed/NCBI
|
|
90
|
Hori H, Yano S, Koufuji K, Takeda J and
Shirouzu K: CD9 expression in gastric cancer and its significance.
J Surg Res. 117:208–215. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Setoguchi T, Kikuchi H, Yamamoto M, Baba
M, Ohta M, Kamiya K, Tanaka T, Baba S, Goto-Inoue N, Setou M, et
al: Microarray analysis identifies versican and CD9 as potent
prognostic markers in gastric gastrointestinal stromal tumors.
Cancer Sci. 102:883–889. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Zhao LJ, Fan QQ, Li YY, Ren HM, Zhang T,
Liu S, Maa M, Zheng YC and Liu HM: LSD1 deletion represses gastric
cancer migration by upregulating a novel miR-142-5p target protein
CD9. Pharmacol Res. 159:1049912020. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Wunder JS, Eppert K, Burrow SR, Gokgoz N,
Bell RS and Andrulis IL: Co-amplification and overexpression of
CDK4, SAS and MDM2 occurs frequently in human parosteal
osteosarcomas. Oncogene. 18:783–788. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Ma X, Qiu S, Tang X, Song Q, Wang P, Wang
J, Xia Q, Wang Z, Zhao Q and Lu M: TSPAN31 regulates the
proliferation, migration, and apoptosis of gastric cancer cells
through the METTL1/CCT2 pathway. Transl Oncol. 20:1014232022.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Oren R, Takahashi S, Doss C, Levy R and
Levy S: TAPA-1, the target of an antiproliferative antibody,
defines a new family of transmembrane proteins. Mol Cell Biol.
10:4007–4015. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Levy S, Todd SC and Maecker HT: CD81
(TAPA-1): A molecule involved in signal transduction and cell
adhesion in the immune system. Annu Rev Immunol. 16:89–109. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Dong JT, Suzuki H, Pin SS, Bova GS,
Schalken JA, Isaacs WB, Barrett JC and Isaacs JT: Down-regulation
of the KAI1 metastasis suppressor gene during the progression of
human prostatic cancer infrequently involves gene mutation or
allelic loss. Cancer Res. 56:4387–4390. 1996.PubMed/NCBI
|
|
98
|
García-Frigola C, Burgaya F, Calbet M, de
Lecea L and Soriano E: Mouse Tspan-5, a member of the tetraspanin
superfamily, is highly expressed in brain cortical structures.
Neuroreport. 11:3181–3185. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Li PY, Lv J, Qi WW, Zhao SF, Sun LB, Liu
N, Sheng J and Qiu WS: Tspan9 inhibits the proliferation, migration
and invasion of human gastric cancer SGC7901 cells via the ERK1/2
pathway. Oncol Rep. 36:448–454. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Qi Y, Qi W, Liu S, Sun L, Ding A, Yu G, Li
H, Wang Y, Qiu W and Lv J: TSPAN9 suppresses the chemosensitivity
of gastric cancer to 5-fluorouracil by promoting autophagy. Cancer
Cell Int. 20:42020. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Sayiner M, Golabi P and Younossi ZM:
Disease burden of hepatocellular carcinoma: A global perspective.
Dig Dis Sci. 64:910–917. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Zhang K, Lai X, Song J, He L, Wang L, Ou
G, Tian X, Wang L, Deng J, Zhang J, et al: A novel cell culture
model reveals the viral interference during hepatitis B and C virus
coinfection. Antiviral Res. 189:1050612021. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Chen L, Wang Z, Zhan X, Li DC, Zhu YY and
Zhu J: Association of NET-1 gene expression with human
hepatocellular carcinoma. Int J Surg Pathol. 15:346–353. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Wu B, Shang H, Liang X, Sun Y, Jing H, Han
X and Cheng W: Preparation of novel targeting nanobubbles
conjugated with small interfering RNA for concurrent molecular
imaging and gene therapy in vivo. FASEB J. 33:14129–14136. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Wu B, Qiao Q, Han X, Jing H, Zhang H,
Liang H and Cheng W: Targeted nanobubbles in low-frequency
ultrasound-mediated gene transfection and growth inhibition of
hepatocellular carcinoma cells. Tumour Biol. 37:12113–12121. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Kanetaka K, Sakamoto M, Yamamoto Y,
Yamasaki S, Lanza F, Kanematsu T and Hirohashi S: Overexpression of
tetraspanin CO-029 in hepatocellular carcinoma. J Hepatol.
35:637–642. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Fang T, Lin J, Wang Y, Chen G, Huang J,
Chen J, Zhao Y, Sun R, Liang C and Liu B: Tetraspanin-8 promotes
hepatocellular carcinoma metastasis by increasing ADAM12m
expression. Oncotarget. 7:40630–40643. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Herlevsen M, Schmidt DS, Miyazaki K and
Zöller M: The association of the tetraspanin D6.1A with the
alpha6beta4 integrin supports cell motility and liver metastasis
formation. J Cell Sci. 116:4373–4390. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Sanjmyatav J, Steiner T, Wunderlich H,
Diegmann J, Gajda M and Junker K: A specific gene expression
signature characterizes metastatic potential in clear cell renal
cell carcinoma. J Urol. 186:289–294. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Tokuhara T, Hasegawa H, Hattori N, Ishida
H, Taki T, Tachibana S, Sasaki S and Miyake M: Clinical
significance of CD151 gene expression in non-small cell lung
cancer. Clin Cancer Res. 7:4109–4114. 2001.PubMed/NCBI
|
|
112
|
Devbhandari RP, Shi GM, Ke AW, Wu FZ,
Huang XY, Wang XY, Shi YH, Ding ZB, Xu Y, Dai Z, et al: Profiling
of the tetraspanin CD151 web and conspiracy of CD151/integrin β1
complex in the progression of hepatocellular carcinoma. PLoS One.
6:e249012011. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Shi GM, Ke AW, Zhou J, Wang XY, Xu Y, Ding
ZB, Devbhandari RP, Huang XY, Qiu SJ, Shi YH, et al: CD151
modulates expression of matrix metalloproteinase 9 and promotes
neoangiogenesis and progression of hepatocellular carcinoma.
Hepatology. 52:183–196. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Zhang PF, Wang F, Wu J, Wu Y, Huang W, Liu
D, Huang XY, Zhang XM and Ke AW: LncRNA SNHG3 induces EMT and
sorafenib resistance by modulating the miR-128/CD151 pathway in
hepatocellular carcinoma. J Cell Physiol. 234:2788–2794. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Liu T, Zu CH, Wang SS, Song HL, Wang ZL,
Xu XN, Liu HS, Wang YL and Shen ZY: PIK3C2A mRNA functions as a
miR-124 sponge to facilitate CD151 expression and enhance
malignancy of hepatocellular carcinoma cells. Oncotarget.
7:43376–43389. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Kim JH, Badawi M, Park JK, Jiang J, Mo X,
Roberts LR and Schmittgen TD: Anti-invasion and anti-migration
effects of miR-199a-3p in hepatocellular carcinoma are due in part
to targeting CD151. Int J Oncol. 49:2037–2045. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Schreyer L, Mittermeier C, Franz MJ, Meier
MA, Martin DE, Maier KC, Huebner K, Schneider-Stock R, Singer S,
Holzer K, et al: Tetraspanin 5 (TSPAN5), a novel gatekeeper of the
tumor suppressor DLC1 and myocardin-related transcription factors
(MRTFs), controls HCC growth and senescence. Cancers (Basel).
13:53732021. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Guo XZ, Friess H, Di Mola FF, Heinicke JM,
Abou-Shady M, Graber HU, Baer HU, Zimmermann A, Korc M and Büchler
MW: KAI1, a new metastasis suppressor gene, is reduced in
metastatic hepatocellular carcinoma. Hepatology. 28:1481–1488.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Yu G, Bing Y, Li W, Xia L and Liu Z:
Hepatitis B virus inhibits the expression of CD82 through
hypermethylation of its promoter in hepatoma cells. Mol Med Rep.
10:2580–2586. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Gilsanz A, Sánchez-Martín L,
Gutiérrez-López MD, Ovalle S, Machado-Pineda Y, Reyes R, Swart GW,
Figdor CG, Lafuente EM and Cabañas C: ALCAM/CD166 adhesive function
is regulated by the tetraspanin CD9. Cell Mol Life Sci. 70:475–493.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Wang J, Ma L, Weng W, Qiao Y, Zhang Y, He
J, Wang H, Xiao W, Li L, Chu Q, et al: Mutual interaction between
YAP and CREB promotes tumorigenesis in liver cancer. Hepatology.
58:1011–1120. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Ma L, Wang J, Lin J, Pan Q, Yu Y and Sun
F: Cluster of differentiation 166 (CD166) regulated by
phosphatidylinositide 3-Kinase (PI3K)/AKT signaling to exert its
anti-apoptotic role via yes-associated protein (YAP) in liver
cancer. J Biol Chem. 289:6921–6933. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Jentzsch V, Davis JAA and Djamgoz MBA:
Pancreatic cancer (PDAC): Introduction of evidence-based
complementary measures into integrative clinical management.
Cancers (Basel). 12:30962020. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Zeitouni D, Pylayeva-Gupta Y, Der CJ and
Bryant KL: KRAS mutant pancreatic cancer: No lone path to an
effective treatment. Cancers (Basel). 8:452016. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Ye H, Li T, Wang H, Wu J, Yi C, Shi J,
Wang P, Song C, Dai L, Jiang G, et al: TSPAN1, TMPRSS4, SDR16C5,
and CTSE as novel panel for pancreatic cancer: A bioinformatics
analysis and experiments validation. Front Immunol. 12:6495512021.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Zhou C, Liang Y, Zhou L, Yan Y, Liu N,
Zhang R, Huang Y, Wang M, Tang Y, Ali DW, et al: TSPAN1 promotes
autophagy flux and mediates cooperation between WNT-CTNNB1
signaling and autophagy via the MIR454-FAM83A-TSPAN1 axis in
pancreatic cancer. Autophagy. 17:3175–3195. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Liu S, Cai Y, Changyong E, Sheng J and
Zhang X: Screening and validation of independent predictors of poor
survival in pancreatic cancer. Pathol Oncol Res. 27:16098682021.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Wang L, Gao P, Yuan P, Zhou P, Fan H, Lin
X, Yuan X, Zhu M, Fan X, Lu Y and Wang Z: miR-573 suppresses
pancreatic cancer cell proliferation, migration, and invasion
through targeting TSPAN1. Strahlenther Onkol. 197:438–448. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Ma C, Cui Z, Wang Y, Zhang L, Wen J, Guo
H, Li N and Zhang W: Bioinformatics analysis reveals TSPAN1 as a
candidate biomarker of progression and prognosis in pancreatic
cancer. Bosn J Basic Med Sci. 21:47–60. 2021.PubMed/NCBI
|
|
131
|
Wang S, Liu X, Khan AA, Li H, Tahir M, Yan
X, Wang J and Huang H: miR-216a-mediated upregulation of TSPAN1
contributes to pancreatic cancer progression via transcriptional
regulation of ITGA2. Am J Cancer Res. 10:1115–1129. 2020.PubMed/NCBI
|
|
132
|
Zhang X, Shi G, Gao F, Liu P, Wang H and
Tan X: TSPAN1 upregulates MMP2 to promote pancreatic cancer cell
migration and invasion via PLCγ. Oncol Rep. 41:2117–2125.
2019.PubMed/NCBI
|
|
133
|
Mayado A, Orfao A, Mentink A, Gutierrez
ML, Muñoz-Bellvis L and Terstappen LWMM: Detection of circulating
tumor cells in blood of pancreatic ductal adenocarcinoma patients.
Cancer Drug Resist. 3:83–97. 2020.PubMed/NCBI
|
|
134
|
Wang H, Rana S, Giese N, Büchler MW and
Zöller M: Tspan8, CD44v6 and alpha6beta4 are biomarkers of
migrating pancreatic cancer-initiating cells. Int J Cancer.
133:416–426. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Yue S, Mu W and Zöller M: Tspan8 and CD151
promote metastasis by distinct mechanisms. Eur J Cancer.
49:2934–2948. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Yue S, Mu W, Erb U and Zöller M: The
tetraspanins CD151 and Tspan8 are essential exosome components for
the crosstalk between cancer initiating cells and their
surrounding. Oncotarget. 6:2366–2384. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Greenow K and Clarke AR: Controlling the
stem cell compartment and regeneration in vivo: The role of
pluripotency pathways. Physiol Rev. 92:75–99. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Sales KM, Winslet MC and Seifalian AM:
Stem cells and cancer: An overview. Stem Cell Rev. 3:249–255. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Heiler S, Wang Z and Zöller M: Pancreatic
cancer stem cell markers and exosomes-the incentive push. World J
Gastroenterol. 22:5971–6007. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Wu M, Li X, Liu R, Yuan H, Liu W and Liu
Z: Development and validation of a metastasis-related gene
signature for predicting the overall survival in patients with
pancreatic ductal adenocarcinoma. J Cancer. 11:6299–6318. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Luo L, Li Y, Huang C, Lin Y, Su Y, Cen H,
Chen Y, Peng S, Ren T, Xie R and Zeng L: A new 7-gene survival
score assay for pancreatic cancer patient prognosis prediction. Am
J Cancer Res. 11:495–512. 2021.PubMed/NCBI
|
|
142
|
Crnogorac-Jurcevic T, Efthimiou E, Capelli
P, Blaveri E, Baron A, Terris B, Jones M, Tyson K, Bassi C, Scarpa
A and Lemoine NR: Gene expression profiles of pancreatic cancer and
stromal desmoplasia. Oncogene. 20:7437–7446. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Feng J, Huang C, Wren JD, Wang DW, Yan J,
Zhang J, Sun Y, Han X and Zhang XA: Tetraspanin CD82: A suppressor
of solid tumors and a modulator of membrane heterogeneity. Cancer
Metastasis Rev. 34:619–633. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Liu WM and Zhang XA: KAI1/CD82, a tumor
metastasis suppressor. Cancer Lett. 240:183–194. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Yan W, Huang J, Zhang Q and Zhang J: Role
of metastasis suppressor KAI1/CD82 in different cancers. J Oncol.
2021:99244732021. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Liu X, Guo XZ, Zhang WW, Lu ZZ, Zhang QW,
Duan HF and Wang LS: KAI1 inhibits HGF-induced invasion of
pancreatic cancer by sphingosine kinase activity. Hepatobiliary
Pancreat Dis Int. 10:201–208. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Miller KD, Nogueira L, Devasia T, Mariotto
AB, Yabroff KR, Jemal A, Kramer J and Siegel RL: Cancer treatment
and survivorship statistics, 2022. CA Cancer J Clin. 72:409–436.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Lee CH, Im EJ, Moon PG and Baek MC:
Discovery of a diagnostic biomarker for colon cancer through
proteomic profiling of small extracellular vesicles. BMC Cancer.
18:10582018. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Guo JN, Chen D, Deng SH, Huang JR, Song
JX, Li XY, Cui BB and Liu YL: Identification and quantification of
immune infiltration landscape on therapy and prognosis in left- and
right-sided colon cancer. Cancer Immunol Immunother. 71:1313–1330.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Min J, Yang S, Cai Y, Vanderwall DR, Wu Z,
Li S, Liu S, Liu B, Wang J, Ding Y, et al: Tetraspanin Tspan8
restrains interferon signaling to stabilize intestinal epithelium
by directing endocytosis of interferon receptor. Cell Mol Life Sci.
80:1542023. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Kuhn S, Koch M, Nübel T, Ladwein M,
Antolovic D, Klingbeil P, Hildebrand D, Moldenhauer G, Langbein L,
Franke WW, et al: A complex of EpCAM, claudin-7, CD44 variant
isoforms, and tetraspanins promotes colorectal cancer progression.
Mol Cancer Res. 5:553–567. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Visvader JE: Cells of origin in cancer.
Nature. 469:314–322. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Wang Z and Zöller M: Exosomes, metastases,
and the miracle of cancer stem cell markers. Cancer Metastasis Rev.
38:259–295. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Greco C, Bralet MP, Ailane N,
Dubart-Kupperschmitt A, Rubinstein E, Le Naour F and Boucheix C:
E-cadherin/p120-catenin and tetraspanin Co-029 cooperate for cell
motility control in human colon carcinoma. Cancer Res.
70:7674–7583. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Knoblich K, Wang HX, Sharma C, Fletcher
AL, Turley SJ and Hemler ME: Tetraspanin TSPAN12 regulates tumor
growth and metastasis and inhibits β-catenin degradation. Cell Mol
Life Sci. 71:1305–1314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Chiang SF, Kan CY, Hsiao YC, Tang R, Hsieh
LL, Chiang JM, Tsai WS, Yeh CY, Hsieh PS, Liang Y, et al: Bone
marrow stromal antigen 2 is a novel plasma biomarker and
prognosticator for colorectal carcinoma: A secretome-based
verification study. Dis Markers. 2015:8740542015. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Hashida H, Takabayashi A, Tokuhara T,
Hattori N, Taki T, Hasegawa H, Satoh S, Kobayashi N, Yamaoka Y and
Miyake M: Clinical significance of transmembrane 4 superfamily in
colon cancer. Br J Cancer. 89:158–167. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Mori M, Mimori K, Shiraishi T, Haraguchi
M, Ueo H, Barnard GF and Akiyoshi T: Motility related protein 1
(MRP1/CD9) expression in colon cancer. Clin Cancer Res.
4:1507–1510. 1998.PubMed/NCBI
|
|
161
|
Wu DH, Liu L, Chen LH and Ding YQ: KAI1
gene expression in colonic carcinoma and its clinical
significances. World J Gastroenterol. 10:2245–2249. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Lee JH, Bae JA, Lee JH, Seo YW, Kho DH,
Sun EG, Lee SE, Cho SH, Joo YE, Ahn KY, et al: Glycoprotein 90K,
downregulated in advanced colorectal cancer tissues, interacts with
CD9/CD82 and suppresses the Wnt/beta-catenin signal via ISGylation
of beta-catenin. Gut. 59:907–917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Morgan E, Soerjomataram I, Rumgay H,
Coleman HG, Thrift AP, Vignat J, Laversanne M, Ferlay J and Arnold
M: The Global landscape of esophageal squamous cell carcinoma and
esophageal adenocarcinoma incidence and mortality in 2020 and
projections to 2040: New estimates from GLOBOCAN 2020.
Gastroenterology. 163:649–658.e2. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
van den Brandt PA: The impact of a healthy
lifestyle on the risk of esophageal and gastric cancer subtypes.
Eur J Epidemiol. 37:931–945. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Botelho NK, Schneiders FI, Lord SJ,
Freeman AK, Tyagi S, Nancarrow DJ, Hayward NK, Whiteman DC and Lord
RV: Gene expression alterations in formalin-fixed,
paraffin-embedded Barrett esophagus and esophageal adenocarcinoma
tissues. Cancer Biol Ther. 10:172–179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Zhao WS, Yan WP, Chen DB, Dai L, Yang YB,
Kang XZ, Fu H, Chen P, Deng KJ, Wang XY, et al: Genome-scale CRISPR
activation screening identifies a role of ELAVL2-CDKN1A axis in
paclitaxel resistance in esophageal squamous cell carcinoma. Am J
Cancer Res. 9:1183–1200. 2019.PubMed/NCBI
|
|
167
|
Fisher OM, Levert-Mignon AJ, Lehane CW,
Botelho NK, Maag JL, Thomas ML, Edwards M, Lord SJ, Bobryshev YV,
Whiteman DC and Lord RV: CD151 Gene and protein expression provides
independent prognostic information for patients with adenocarcinoma
of the esophagus and gastroesophageal junction treated by
esophagectomy. Ann Surg Oncol. 23 (Suppl 5):S746–S754. 2016.
View Article : Google Scholar
|
|
168
|
Scully C and Porter S: ABC of oral health.
Oral cancer. BMJ. 321:97–100. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Scully C and Bedi R: Ethnicity and oral
cancer. Lancet Oncol. 1:37–42. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
D'souza S and Addepalli V: Preventive
measures in oral cancer: An overview. Biomed Pharmacother.
107:72–80. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Hiroshima K, Shiiba M, Oka N, Hayashi F,
Ishida S, Fukushima R, Koike K, Iyoda M, Nakashima D, Tanzawa H and
Uzawa K: Tspan15 plays a crucial role in metastasis in oral
squamous cell carcinoma. Exp Cell Res. 384:1116222019. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Nankivell P, Williams H, McConkey C,
Webster K, High A, MacLennan K, Senguven B, Rabbitts P and Mehanna
H: Tetraspanins CD9 and CD151, epidermal growth factor receptor and
cyclooxygenase-2 expression predict malignant progression in oral
epithelial dysplasia. Br J Cancer. 109:2864–2874. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Imai Y, Sasaki T, Shinagawa Y, Akimoto K
and Fujibayashi T: Expression of metastasis suppressor gene
(KAI1/CD82) in oral squamous cell carcinoma and its
clinico-pathological significance. Oral Oncol. 38:557–561. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Farhadieh RD, Smee R, Ow K, Yang JL,
Russell PJ, Crouch R, Jackson P and Jacobson IV: Down-regulation of
KAI1/CD82 protein expression in oral cancer correlates with reduced
disease free survival and overall patient survival. Cancer Lett.
213:91–98. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Matsumura N, Zembutsu H, Yamaguchi K,
Sasaki K, Tsuruma T, Nishidate T, Denno R and Hirata K:
Identification of novel molecular markers for detection of gastric
cancer cells in the peripheral blood circulation using genome-wide
microarray analysis. Exp Ther Med. 2:705–713. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Lin H, Zhou AJ, Zhang JY, Liu SF and Gu
JX: MiR-324-5p reduces viability and induces apoptosis in gastric
cancer cells through modulating TSPAN8. J Pharm Pharmacol.
70:1513–1520. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Zhai R, Kan X, Wang B, Du H, Long Y, Wu H,
Tao K, Wang G, Bao L, Li F and Zhang W: miR-152 suppresses gastric
cancer cell proliferation and motility by targeting CD151. Tumour
Biol. 35:11367–11373. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Blanco E, Hsiao A, Ruiz-Esparza GU, Landry
MG, Meric-Bernstam F and Ferrari M: Molecular-targeted
nanotherapies in cancer: Enabling treatment specificity. Mol Oncol.
5:492–503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Kim TK, Park CS, Jeoung MH, Lee WR, Go NK,
Choi JR, Lee TS, Shim H and Lee S: Generation of a human antibody
that inhibits TSPAN8-mediated invasion of metastatic colorectal
cancer cells. Biochem Biophys Res Commun. 468:774–780. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Park CS, Kim TK, Kim HG, Kim YJ, Jeoung
MH, Lee WR, Go NK, Heo K and Lee S: Therapeutic targeting of
tetraspanin8 in epithelial ovarian cancer invasion and metastasis.
Oncogene. 35:4540–4548. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Ke AW, Zhang PF, Shen YH, Gao PT, Dong ZR,
Zhang C, Cai JB, Huang XY, Wu C, Zhang L, et al: Generation and
characterization of a tetraspanin CD151/integrin α6β1-binding
domain competitively binding monoclonal antibody for inhibition of
tumor progression in HCC. Oncotarget. 7:6314–6322. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Jin L and Cambier JC: SMIP-016 in action:
CD37 as a death receptor. Cancer Cell. 21:597–598. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Hwang JR, Jo K, Lee Y, Sung BJ, Park YW
and Lee JH: Upregulation of CD9 in ovarian cancer is related to the
induction of TNF-α gene expression and constitutive NF-κB
activation. Carcinogenesis. 33:77–83. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Longo N, Yáñez-Mó M, Mittelbrunn M, de la
Rosa G, Muñoz ML, Sánchez-Madrid F and Sánchez-Mateos P: Regulatory
role of tetraspanin CD9 in tumor-endothelial cell interaction
during transendothelial invasion of melanoma cells. Blood.
98:3717–3726. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Rock KL, Farfán-Arribas DJ, Colbert JD and
Goldberg AL: Re-examining class-I presentation and the DRiP
hypothesis. Trends Immunol. 35:144–152. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Unternaehrer JJ, Chow A, Pypaert M, Inaba
K and Mellman I: The tetraspanin CD9 mediates lateral association
of MHC class II molecules on the dendritic cell surface. Proc Natl
Acad Sci USA. 104:234–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Suzuki M, Tachibana I, Takeda Y, He P,
Minami S, Iwasaki T, Kida H, Goya S, Kijima T, Yoshida M, et al:
Tetraspanin CD9 negatively regulates lipopolysaccharide-induced
macrophage activation and lung inflammation. J Immunol.
182:6485–6493. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Rocha-Perugini V, Martínez Del Hoyo G,
González-Granado JM, Ramírez-Huesca M, Zorita V, Rubinstein E,
Boucheix C and Sánchez-Madrid F: CD9 regulates major
histocompatibility complex class II trafficking in monocyte-derived
dendritic cells. Mol Cell Biol. 37:e00202–17. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Jones EL, Wee JL, Demaria MC, Blakeley J,
Ho PK, Vega-Ramos J, Villadangos JA, van Spriel AB, Hickey MJ,
Hämmerling GJ and Wright MD: Dendritic cell migration and antigen
presentation are coordinated by the opposing functions of the
tetraspanins CD82 and CD37. J Immunol. 196:978–987. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Gartlan KH, Wee JL, Demaria MC, Nastovska
R, Chang TM, Jones EL, Apostolopoulos V, Pietersz GA, Hickey MJ,
van Spriel AB and Wright MD: Tetraspanin CD37 contributes to the
initiation of cellular immunity by promoting dendritic cell
migration. Eur J Immunol. 43:1208–1219. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Todros-Dawda I, Kveberg L, Vaage JT and
Inngjerdingen M: The tetraspanin CD53 modulates responses from
activating NK cell receptors, promoting LFA-1 activation and
dampening NK cell effector functions. PLoS One. 9:e978442014.
View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Petersen SH, Odintsova E, Haigh TA,
Rickinson AB, Taylor GS and Berditchevski F: The role of
tetraspanin CD63 in antigen presentation via MHC class II. Eur J
Immunol. 41:2556–2561. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Sheng KC, van Spriel AB, Gartlan KH, Sofi
M, Apostolopoulos V, Ashman L and Wright MD: Tetraspanins CD37 and
CD151 differentially regulate Ag presentation and T-cell
co-stimulation by DC. Eur J Immunol. 39:50–55. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Colbert JD, Cruz FM, Baer CE and Rock KL:
Tetraspanin-5-mediated MHC class I clustering is required for
optimal CD8 T cell activation. Proc Natl Acad Sci USA.
119:e21221881192022. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Schäfer D, Tomiuk S, Küster LN, Rawashdeh
WA, Henze J, Tischler-Höhle G, Agorku DJ, Brauner J, Linnartz C,
Lock D, et al: Identification of CD318, TSPAN8 and CD66c as target
candidates for CAR T cell based immunotherapy of pancreatic
adenocarcinoma. Nat Commun. 12:14532021. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Kohmo S, Kijima T, Otani Y, Mori M, Minami
T, Takahashi R, Nagatomo I, Takeda Y, Kida H, Goya S, et al: Cell
surface tetraspanin CD9 mediates chemoresistance in small cell lung
cancer. Cancer Res. 70:8025–8035. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Ullah M, Akbar A, Ng NN, Concepcion W and
Thakor AS: Mesenchymal stem cells confer chemoresistance in breast
cancer via a CD9 dependent mechanism. Oncotarget. 10:3435–3450.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Pan SJ, Wu YB, Cai S, Pan YX, Liu W, Bian
LG, Sun B and Sun QF: Over-expression of tetraspanin 8 in malignant
glioma regulates tumor cell progression. Biochem Biophys Res
Commun. 458:476–482. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Zhu R, Gires O, Zhu L, Liu J, Li J, Yang
H, Ju G, Huang J, Ge W, Chen Y, et al: TSPAN8 promotes cancer cell
stemness via activation of sonic Hedgehog signaling. Nat Commun.
10:28632019. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Tominaga N, Hagiwara K, Kosaka N, Honma K,
Nakagama H and Ochiya T: RPN2-mediated glycosylation of tetraspanin
CD63 regulates breast cancer cell malignancy. Mol Cancer.
13:1342014. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Ye M, Wei T, Wang Q, Sun Y, Tang R, Guo L
and Zhu W: TSPAN12 promotes chemoresistance and proliferation of
SCLC under the regulation of miR-495. Biochem Biophys Res Commun.
486:349–356. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Floren M, Restrepo Cruz S, Termini CM,
Marjon KD, Lidke KA and Gillette JM: Tetraspanin CD82 drives acute
myeloid leukemia chemoresistance by modulating protein kinase C
alpha and β1 integrin activation. Oncogene. 39:3910–3925. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Quagliano A, Gopalakrishnapillai A, Kolb
EA and Barwe SP: CD81 knockout promotes chemosensitivity and
disrupts in vivo homing and engraftment in acute lymphoblastic
leukemia. Blood Adv. 4:4393–4405. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Li L, Yang D, Cui D, Li Y, Nie Z, Wang J
and Liang L: Quantitative proteomics analysis of the role of
tetraspanin-8 in the drug resistance of gastric cancer. Int J
Oncol. 52:473–484. 2018.PubMed/NCBI
|
|
205
|
Gao X, Ran N, Dong X, Zuo B, Yang R, Zhou
Q, Moulton HM, Seow Y and Yin H: Anchor peptide captures, targets,
and loads exosomes of diverse origins for diagnostics and therapy.
Sci Transl Med. 10:eaat01952018. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Huang Y, Zucker B, Zhang S, Elias S, Zhu
Y, Chen H, Ding T, Li Y, Sun Y, Lou J, et al: Migrasome formation
is mediated by assembly of micron-scale tetraspanin macrodomains.
Nat Cell Biol. 21:991–1002. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Jiao H, Jiang D, Hu X, Du W, Ji L, Yang Y,
Li X, Sho T, Wang X, Li Y, et al: Mitocytosis, a migrasome-mediated
mitochondrial quality-control process. Cell. 184:2896–2910.e13.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Yu S and Yu L: Migrasome biogenesis and
functions. FEBS J. 289:7246–7254. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Schmidt-Pogoda A, Strecker JK, Liebmann M,
Massoth C, Beuker C, Hansen U, König S, Albrecht S, Bock S, Breuer
J, et al: Dietary salt promotes ischemic brain injury and is
associated with parenchymal migrasome formation. PLoS One.
13:e02098712018. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Chen L, Ma L and Yu L: WGA is a probe for
migrasomes. Cell Discov. 5:132019. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Zheng Y, Lang Y, Qi B, Wang Y, Gao W and
Li T: TSPAN4 is a prognostic and immune target in Glioblastoma
multiforme. Front Mol Biosci. 9:10300572023. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Zhang K, Zhu Z, Jia R, Wang NA, Shi M,
Wang Y, Xiang S, Zhang Q and Xu L: CD151-enriched migrasomes
mediate hepatocellular carcinoma invasion by conditioning cancer
cells and promoting angiogenesis. J Exp Clin Cancer Res.
43:1602024. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Qin Y, Yang J, Liang C, Liu J, Deng Z, Yan
B, Fu Y, Luo Y, Li X, Wei X and Li W: Pan-cancer analysis
identifies migrasome-related genes as a potential immunotherapeutic
target: A bulk omics research and single cell sequencing
validation. Front Immunol. 13:9948282022. View Article : Google Scholar : PubMed/NCBI
|
